header
Image from OpenLibrary

The relation between angiotensin converting enzyme inhibitors and hepatoma in Egyptian patients / Mohamed Elsherbiny Ismail Saleh ; Supervised Ahmad M. Farag , Amr Saad Mohamed , Hossam Darwish

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mohamed Elsherbiny Ismail Saleh , 2018Description: 217 P. ; 25cmOther title:
  • العلاقة بين مثبطات الإنزيم المحول للأنجيوتنسين وسرطان الكبد عند المرضى المصريين [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry Summary: This study was conducted to investigate the association between angiotensin converting enzyme inhibitors (ACE-I) and hepatocellular carcinoma (HCC) in Egyptians forty patients with HCC, (23 patients with Child-Pugh B and 17 patients with Child-Pugh C) compared with eight normal control humans, which diagnosed by physicians of the Damietta Cancer Institute according to (AASLD) Practice Guidelines. Patients received Captopril at 50 mg/day for 3 months; the samples were collected before and directly after the end of given of Captopril. Serum Alfa fetoprotein (AFP), Vascular Endothelial Growth Factor (VEGF) and liver functions were evaluated before and after of administration of Captopril. P- Value, R- ratio and prognostic value, Receiver Operating Characteristic (ROC) curves were used for association studies and to assess the differences in the values among the groups. There was statistically significant improvement of serum liver functions, and decreased serum AFP and VEGF levels in HCC patients at post-administration compared with pre-administration of Captopril. In addition, at pre-administration there was significant correlation of serum VEGF with serum AFP (r = 0.492) and at post- administration with serum AFP (r = 0.619). The prognostic value of serum AFP and VEGF levels were assessed by ROC curve showing an area under curve (AUC) of (0.689, 0.907), respectively for identifying patients with HCC pre- and post-administration of Captopril. In conclusion, ACE inhibitors (as Captopril), were significantly inhibit tumor growth and angiogenesis along with suppression of the serum VEGF and AFP levels. This may be used in the clinical trials as anti-angiogenic agents against cancer, and may be applicable as an anticancer agent providing a new strategy for cancer therapy
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.02.M.Sc.2018.Mo.R (Browse shelf(Opens below)) Not for loan 01010110079745000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.02.M.Sc.2018.Mo.R (Browse shelf(Opens below)) 79745.CD Not for loan 01020110079745000

Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry

This study was conducted to investigate the association between angiotensin converting enzyme inhibitors (ACE-I) and hepatocellular carcinoma (HCC) in Egyptians forty patients with HCC, (23 patients with Child-Pugh B and 17 patients with Child-Pugh C) compared with eight normal control humans, which diagnosed by physicians of the Damietta Cancer Institute according to (AASLD) Practice Guidelines. Patients received Captopril at 50 mg/day for 3 months; the samples were collected before and directly after the end of given of Captopril. Serum Alfa fetoprotein (AFP), Vascular Endothelial Growth Factor (VEGF) and liver functions were evaluated before and after of administration of Captopril. P- Value, R- ratio and prognostic value, Receiver Operating Characteristic (ROC) curves were used for association studies and to assess the differences in the values among the groups. There was statistically significant improvement of serum liver functions, and decreased serum AFP and VEGF levels in HCC patients at post-administration compared with pre-administration of Captopril. In addition, at pre-administration there was significant correlation of serum VEGF with serum AFP (r = 0.492) and at post- administration with serum AFP (r = 0.619). The prognostic value of serum AFP and VEGF levels were assessed by ROC curve showing an area under curve (AUC) of (0.689, 0.907), respectively for identifying patients with HCC pre- and post-administration of Captopril. In conclusion, ACE inhibitors (as Captopril), were significantly inhibit tumor growth and angiogenesis along with suppression of the serum VEGF and AFP levels. This may be used in the clinical trials as anti-angiogenic agents against cancer, and may be applicable as an anticancer agent providing a new strategy for cancer therapy

Issued also as CD

There are no comments on this title.

to post a comment.